Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We’ll see....If I were you I get in now
I wouldn’t be so sure, we are about to track north once we get into the 2’s I have feeling the run will begin.
Things are just warming up..:) This baby is about to grow some legs soon enough, once
Revs roll in I see .25 or more in the horizon.
This is the same trading pattern as yesterday...Hmmmm
Just imagine if we JV’d up with GWPH
The time to get in is now !
Premier Biomedical Launches Hemp Oil Based Topical Pain Relief Ointment
Brings To Five The Number Of Products Introduced In First Twelve Months
January 23, 2018 10:25 ET | Source: Premier Biomedical, Inc.
JACKSON CENTER, Pa., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Premier Biomedical, Inc. (OTC:BIEI) announced introduction of a new hemp oil based topical ointment to complement its existing topical pain relief products, which include a 96-hour topical skin patch, oil-based and water-based roll-ons, and an oil-based spray. This two ounce jar ointment, along with the rest of Premier’s products, is made from all-natural, non-GMO, solvent- and pesticide-free ingredients. All of Premier’s pain relief products are available through their website, www.painreliefmeds.com, select pharmacies, and HealthWarehouse.com, the largest mail-order pharmacy in the country.
William A. Hartman, President & CEO of Premier Biomedical, Inc., stated, “We are very excited that in our first 12 months of operation that we have been able to introduce five, very effective pain relieving products. That’s not just my assessment, but rather it is based on feedback and testimonials from our customers. Once people try our products, they will agree that they outperform every other competitive product in relieving pain and suffering, without the dangerous and addictive side-effects associated with opioids.”
For more information please contact:
William A. Hartman
President and CEO
Premier Biomedical, Inc.
Pain Relief Meds
(724) 633-7033
w.hartman@premierbiomedical.com
www.premierbiomedical.com/
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTC:BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company's R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTC marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI." For more information please visit our website: http://www.premierbiomedical.com/.
Manipulation is in play here..
Yea real Huge...See todays...What a Joke
First of all they have to have a product then they need to get it into a clinical study and then approved we are far more advanced then they are.
You sure about that they can be if there working with a big company ,Maybe thats why there quiet because they are getting ready to release something big soon and want to make sure there IIII's are dotted and the TTT's are crossed.
Management is being tight lipped for a reason.
Hold on tight don’t get scared out of what you own here !
Huh...What are you talking about, we are better positioned then most MJ Companies out there.
He is a shady character and should go..Think the trumps are about to get an eviction notice to leave the White House next.
Thanks to Sessions it dampened the whole sector..it’s just a little set back but we will make out in the end hold on to your shares and accumulate when you can.
I have a feeling it will be short lived..lol
Most Definitely ! I have a feeling the .50 will go quick
To all investors and non investors the time is now to get on board.
We are about to see a huge move here soon.
You are correct, They have been diligently working on this since March.
I think there is we just havent seen it yet, Things are being tight lipped on the front.
This is Big....Just read it and let it soak in..
The technology behind the Tablet is protected and provides for the ingestion of virtually any dosage of medical cannabis with a sublingual delivery mechanism, whereby the compounds are absorbed directly into the patient’s blood through the oral epithelial tissue. The Tablet also enables physicians to safely and accurately gauge and monitor the dosage and treatment of each individual patient, something that is essentially impossible to do for patients who administer cannabis by smoking.
The Cannabis Tablet avoids all the disadvantages of smoking regular tobacco products, including the danger of lung cancer and general damage to the respiratory system, produces no significant smell, and easily delivers its payload in fixed dosages.
The sublingual Tablet will be indicated mainly for chronic pain patients suffering from diseases such as Fibromyalgia or neuropathic pain and PTSD patients. The Tablet dissolves within the mouth allowing it to absorb through the oral mucosa and thus skips the first pass through the liver and has a faster response time than regular tablets or pills.
Long-Awaited Update Boosts Shares of OWC Pharmaceutical Research Corp (OTCMKTS: OWCP)
By Michael Luke - December 27, 201790
Share on Facebook Tweet on Twitter
It has been quite some time since we last mentioned OWC Pharmaceutical Research Corp (OTCMKTS: OWCP) here on Street Register, primarily because of the unfortunate fact that the company hasn’t been in the habit of issuing regular press releases in the latter half of 2017.
It was early this summer, the last time the company was communicating with shareholders with any regularity. Perhaps it is no coincidence that shares of OWCP failed to breach their fifty day moving average even once between the months of April and October. But an update from the company has helped turn things around recently, and that’s what we’ll focus on today.
For those of our readers who don’t recall, OWC Pharmaceutical Research Corp (OTCMKTS: OWCP) through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
The beginning of a rebound on the chart stemmed from OWC recently announcing that it had received a new permit from the Israel Medical Cannabis Agency [MCA] to proceed with the safety study of their oral disintegrating, sublingual medical cannabis tablet. The study protocol will be submitted to the Institutional Review Board [IRB] at a leading Israeli academic hospital in the coming weeks. The study is scheduled to begin in Q2 2018.
In October of 2016 OWC announced that it had completed the development of a proprietary cannabinoid-enriched sublingual tablet for the administration of medical cannabis. The Tablet constitutes a smoke-free alternative for patients using medical cannabis.
The technology behind the Tablet is protected and provides for the ingestion of virtually any dosage of medical cannabis with a sublingual delivery mechanism, whereby the compounds are absorbed directly into the patient’s blood through the oral epithelial tissue. The Tablet also enables physicians to safely and accurately gauge and monitor the dosage and treatment of each individual patient, something that is essentially impossible to do for patients who administer cannabis by smoking.
The Cannabis Tablet avoids all the disadvantages of smoking regular tobacco products, including the danger of lung cancer and general damage to the respiratory system, produces no significant smell, and easily delivers its payload in fixed dosages.
The sublingual Tablet will be indicated mainly for chronic pain patients suffering from diseases such as Fibromyalgia or neuropathic pain and PTSD patients. The Tablet dissolves within the mouth allowing it to absorb through the oral mucosa and thus skips the first pass through the liver and has a faster response time than regular tablets or pills.
Commenting on this milestone, Dr. Yehuda Baruch Director of Research and Regulatory Affairs at OWC stated: “We greatly look forward to introducing this breakthrough tablet to the marketplace after completing our testing. The preliminary results with the Tablet have been promising and we are eager to provide patients suffering from debilitating chronic conditions with effective non-opioid solutions.” (Source: PR Newswire)
OWC plans to issue additional updates on its continued research and further developments in early 2018. We will be anxiously awaiting another update, and hope that the company returns to regular communication with its shareholders in the new year.
Just imagine if GW JV’D with OW, This would turn into Godzilla !
Your totally right you hit the nail on the head ! :) we know what we own. Great Post !
I know what I own...period
Show us your actual results of your research claims about what you found ?
Before long major Pharms will be looking to jump on board it’s only a matter of time and OWCP is set right up for the present PPS to become history.
HEALTHOWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Gets A New LicensePublished 6 hours ago on December 26, 2017 By Chris Mann
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has obtained a new license from the Israel Medical Cannabis Agency to advance with the safety trial of its oral disintegrating tablet. The trial protocol will be filed to the Institutional Review Board at a major Israeli academic hospital in the imminent weeks. The trial is planned to begin in Q2 2018.
The details
In 2016, OWC posted that it had concluded the advancement of a CBD-based sublingual tablet for the administration of medicinal cannabis. The tablet comprises a smoke-free option for patients utilizing medical cannabis. The know-how behind the Tablet is protected and offers for the ingestion of almost any dosage of medicinal cannabis with a sublingual delivery system, whereby the compounds are taken directly into the subject’s blood via the oral epithelial tissue.
This tablet also allows physicians to accurately and safely monitor and gauge the treatment and dosage of each patient, something that is mainly impossible to do for subjects who get cannabis by smoking. OWC Pharmaceutical reported that the Cannabis Tablet offers numerous benefits. It offers a delivery modality which evades all the detriments of smoking regular tobacco items, including the general harm to the respiratory system and peril of lung cancer.
The sublingual tablet will be used primarily for chronic pain subjects suffering from ailments such as neuropathic pain or Fibromyalgia and PTSD patients. This tablet melts within the mouth enabling it to get via the oral mucosa and hence skips the initial pass via the liver and has a rapid response time than regular pills or tablets.
Expressing on this achievement, Dr. Yehuda Baruch, the Director of Research & Regulatory Affairs at OWC Pharmaceutical, expressed that they considerably look forward to launching this breakthrough tablet to the market post completing their testing. The preliminary data with the tablet have been extremely promising and they are thrilled to offer people suffering from debilitating chronic problems with effective non-opioid solutions.
Maybe you should
Green like my Christmas Tree :)
I doubt we stay here..it’s a good area to accumulate before we launch upward.
Something Big is going to come of this very soon...
https://seekingalpha.com/filing/3695306
Don’t let these chumps swindle you out of your shares..huh gangbangkitty and his 30 min chart